| Title |
A Review of Autologous Stem Cell Transplantation in Lymphoma
|
|---|---|
| Published in |
Current Hematologic Malignancy Reports, May 2017
|
| DOI | 10.1007/s11899-017-0382-1 |
| Pubmed ID | |
| Authors |
Umar Zahid, Faisal Akbar, Akshay Amaraneni, Muhammad Husnain, Onyee Chan, Irbaz Bin Riaz, Ali McBride, Ahmad Iftikhar, Faiz Anwer |
| Abstract |
Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20-30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients. There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 25% |
| Canada | 2 | 25% |
| Unknown | 4 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 88% |
| Scientists | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 118 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 13% |
| Other | 14 | 12% |
| Student > Master | 10 | 8% |
| Student > Ph. D. Student | 9 | 8% |
| Student > Postgraduate | 9 | 8% |
| Other | 23 | 19% |
| Unknown | 38 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
| Biochemistry, Genetics and Molecular Biology | 8 | 7% |
| Nursing and Health Professions | 5 | 4% |
| Agricultural and Biological Sciences | 3 | 3% |
| Other | 8 | 7% |
| Unknown | 42 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2023.
All research outputs
#7,215,015
of 25,401,784 outputs
Outputs from Current Hematologic Malignancy Reports
#159
of 447 outputs
Outputs of similar age
#106,634
of 324,753 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#3
of 11 outputs
Altmetric has tracked 25,401,784 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 447 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,753 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.